Abstract
Cancer is a disease closely linked to nutrition. In fact, unhealthy eating habits have been causally related to the onset of some tumors. Also, the clinical journey of cancer patients is characterized by the onset of profound changes in nutritional status, i.e., cachexia, as a consequence of the impairment of host’s metabolism and eating behavior. Finally, anticancer therapies may per se alter host’s nutritional status by inducing toxicity and reduced energy intake, as well as by favoring muscle loss. In daily clinical practice, malnutrition is generally not assessed in cancer patients, and nutrition therapy is considered only in the final stages of patients’ clinical journey. This approach is in contrast with consistent and robust clinical evidence showing that malnutrition is a strong predictor of negative outcome in cancer. Therefore, nutrition therapy should be considered from the very beginning of patients’ journey. Highlighting the relevance of preventing/treating cachexia, recent clinical trials showed that when nutrition therapy is provided early and within a multimodal context which includes psychological support and pain control, then survival is extended and quality of life improved in patients with advanced cancer. Furthermore, recent experimental evidence seem to suggest that use of specific nutrients (i.e., omega-3 fatty acids, glutamine, arginine, branched-chain amino acids, etc.) at key time points during anticancer therapies may have an inhibitory influence on tumor growth. In particular, omega-3 fatty acids have been shown to ameliorate tumor inflammatory microenvironment and enhance response rate to chemotherapy. These preliminary data need confirmation in large clinical trials before their translation into clinical practice. Nevertheless, they may help to shift the consideration of oncologists toward nutrition from a procedure for the last days of life into a key component of anticancer therapies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tao M, You C, Zhao R et al (2014) Animal mitochondria: evolution, function, and disease. Curr Mol Med 14(1):115–124
Hervant F, Renault D (2002) Long-term fasting and realimentation in hypogean and epigean isopods: a proposed adaptive strategy for groundwater organisms. J Exp Biol 205:2079–2084
Soeters MR, Soeters PB (2012) The evolutionary benefit of insulin resistance. Clin Nutr 31:1002–1007
Lozano R, Naghavi M, Foreman K et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095–2128
Editorial (2011) Cancer drugs: remedy required. Nat Med 17:231
Laviano A, Molfino A, Rossi Fanelli F (2012) Cancer-treatment toxicity: can nutrition help? Nat Rev Clin Oncol 9(10). doi: 10.1038/nrclinonc.2012.99-c1
Suzuki H, Asakawa A, Amitani H, Nakamura N, Inui A (2013) Cancer cachexia—pathophysiology and management. J Gastroenterol 48:574–594
Fearon K, Arends J, Baracos V (2013) Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 10:90–99
Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489–495
Prado CM, Sawyer MB, Ghosh S et al (2013) Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr 98:1012–1019
Prado CM, Lieffers JR, McCargar LJ et al (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9:629–635
Laviano A, Inui A, Marks DL et al (2008) Neural control of the anorexia-cachexia syndrome. Am J Physiol Endocrinol Metab 295:E1000–E1008
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70
Mantovani A (2009) Cancer: inflaming metastasis. Nature 457:36–37
Borovikova LV, Ivanova S, Zhang M et al (2000) Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405:458–462
Laviano A, Meguid MM, Cascino A, Molfino A, Rossi FF (2009) Tryptophan in wasting diseases: at the crossing between immune function and behavior. Curr Opin Clin Nutr Metab Care 12:392–397
Spencer SK, Pommier AJ, Morgan SR et al (2013) Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy. Br J Cancer 109:2765–2773
Coussens LM, Zitvogel L, Palucka AK (2013) Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339:286–291
Winter A, MacAdams J, Chevalier S (2012) Normal protein anabolic response to hyperaminoacidemia in insulin-resistant patients with lung cancer cachexia. Clin Nutr 31:765–773
Cerchietti LC, Navigante AH, Peluffo GD et al (2004) Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. J Pain Symptom Manage 27:85–95
Laviano A, Rianda S, Molfino A, Rossi Fanelli F (2013) Omega-3 fatty acids in cancer. Curr Opin Clin Nutr Metab Care 16:156–161
Baldwin C, Spiro A, Ahern R, Emery PW (2012) Oral nutrition interventions in malnourished patients with cancer: a systematic review and meta-analysis. J Clin Oncol 104:371–385
Temel JS, Greer JA, Muzikasky A et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742
Smith TJ, Temin S, Alesi ER et al (2012) American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol 30:880–887
de Roode JC, Lefevre T, Hunter MD (2013) Self-medication in animals. Science 340:150–151
Cleeland CS, Allen JD, Roberts SA et al (2012) Reducing the toxicity of cancer therapy: recognizing needs, taking action. Nat Rev Clin Oncol 9:471–478
Laviano A, Rianda S, Rossi Fanelli F (2013) Sarcopenia and chemotherapy dosing in obese patients. Nat Rev Clin Oncol 10:664
Hajjaji N, Bougnoux P (2013) Selective sensitization of tumors to chemotherapy by marine-derived lipids: a review. Cancer Treat Rev 39:473–488
Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C, Le Floch O (2009) Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer 101:1978–1985
Murphy RA, Mourtzakis M, Chu QSC, Baracos VE, Reiman T, Mazurak VC (2011) Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer 117:3774–3780
Zhang G, Panigrahy D, Mahakian LM et al (2013) Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A 110:6530–6535
Fontana L, Partridge L, Longo VD (2010) Extending healthy life span—from yeast to humans. Science 328:321–326
Colman RJ, Anderson RM, Johnson SC et al (2009) Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 325:201–204
Heilbronn LK, de Jonge L, Frisard MI et al (2006) Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals—a randomized controlled trial. JAMA 295:1539–1548
Mattison JA, Roth GS, Beasley TM et al (2012) Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 489:318–321
Maxmen A (2012) Calorie restriction falters in the long run. Nature 488:569
Lee C, Raffaghello L, Longo VD (2012) Starvation, detoxification, and multidrug resistance in cancer therapy. Drug Resist Updat 15:114–122
Laviano A, Rossi Fanelli F (2012) Toxicity in chemotherapy—when less is more. N Engl J Med 366:2319–2320
Lee C, Raffaghello L, Brandhorst S et al (2012) Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med 4:124ra27
Raffaghello L, Safdie F, Bianchi G, Dorff T, Fontana L, Longo VD (2010) Fasting and differential chemotherapy protection in patients. Cell Cycle 9:4474–4476
Abdelwahab MG, Fenton KE, Preul MC et al (2012) The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One 7(5):e36197
Maddocks OD, Berkers CR, Mason SM et al (2013) Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 493:542–546
Peng W, Robertson L, Gallinetti J et al (2013) Surgical stress resistance induced by single amino acid deprivation requires Gcn2 in mice. Sci Transl Med 4:113ra11
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Laviano, A., Gori, C., Stronati, M., Mari, A., Rianda, S. (2014). Nutrition in Oncology: From Treating Cachexia to Targeting the Tumor. In: Folkerts, G., Garssen, J. (eds) Pharma-Nutrition. AAPS Advances in the Pharmaceutical Sciences Series, vol 12. Springer, Cham. https://doi.org/10.1007/978-3-319-06151-1_15
Download citation
DOI: https://doi.org/10.1007/978-3-319-06151-1_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-06150-4
Online ISBN: 978-3-319-06151-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)